SkyePharma to Announce 2006 Interim Results on 28 September

LONDON, Sept. 5  /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKPLSE:Nasdaq:LSE:SKYE) announces today that the Company will issue its interim results for the six months ended 30 June 2006 to the London Stock Exchange at 07:00 a.m. BST on Thursday 28 September 2006. Later that morning the Company will host an analyst presentation, which will be webcast live, to be followed by a US conference call.

Frank Condella, SkyePharma's Chief Executive Officer, will host the analyst presentation and the conference call. Investors and other interested parties may view the live webcast at 10:00 a.m. BST on the Company's website at http://www.skyepharma.com/ under the Investor Relations tab.

US investors and other interested parties may access the conference call at 10:00 a.m. EDT (15:00 BST) by dialling [phone] for US participants and [phone] for international participants. The slides of the presentation will be available on the Company's website at http://www.skyepharma.com/ under the Investor Relations tab.

For those unable to listen to the live broadcast, a replay will be available shortly after the conference call by dialling [phone] for US participants and [phone] for international participants and entering Access Code 1549587.

  For further information please contact:

  SkyePharma PLC                                          [phone]
  Frank Condella, Chief Executive Officer
  Peter Laing, Director of Corporate Communications       [phone]
  Sandra Haughton, US Investor Relations                  [phone]

  Buchanan Communications                                 [phone]
  Tim Anderson / Mark Court / Rebecca Skye Dietrich

  About SkyePharma


SkyePharma PLC develops pharmaceutical products benefiting from world- leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now twelve approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit http://www.skyepharma.com/. 

DATASOURCE: SkyePharma PLC



CONTACT:  SkyePharma PLC, [phone], or Frank Condella, Chief

Executive Officer, or Peter Laing, Director of Corporate Communications,

[phone], or Sandra Haughton, US Investor Relations, [phone];

or Buchanan Communications,  [phone], Tim Anderson, or Mark Court, or

Rebecca Skye Dietrich



Web site:  http://www.skyepharma.com/ 

Copyright